Skip directly to content

Lower Risk of Breast Cancer Recurrence

 

Inspired to Be Informed

 

Lower Risk of Cancer Recurrence

The risk of cancer recurrence was lower for women who switched to AROMASIN®
(exemestane tablets) after 2 to 3 years of treatment with tamoxifen than for women who stayed on tamoxifen for 5 years.

Women who experienced cancer recurrence (local or metastatic recurrence, contralateral breast cancer or death) after almost 3 years (34.5 months) in the study
AROMASIN
Patients
(n=2,352)
213
Tamoxifen
Patients
(n=2,372)
306

Absolute risk reduction

Fewer (4% less) women experienced cancer recurrence in the AROMASIN group than in the tamoxifen group

Relative risk reduction

Women in the study had a 31% lower risk of
cancer recurrence

Relative risk reduction: helps us understand the likelihood (risk) of disease recurrence for patients who switched to AROMASIN versus patients who stayed on tamoxifen.

After 10 years in the study, results continued

Women who experienced cancer recurrence (local or metastatic recurrence, contralateral breast cancer or death) after 10 years (120 months) in the study
AROMASIN
Patients
(n=2,352)
672
Tamoxifen
Patients
(n=2,372)
761

Absolute risk reduction

Fewer (4% less) women experienced cancer recurrence in the AROMASIN group than in the tamoxifen group

Relative risk reduction

Women in the study had a 14% lower risk of
cancer recurrence

Relative risk reduction: helps us understand the likelihood (risk) of disease recurrence for patients who switched to AROMASIN versus patients who stayed on tamoxifen.